文献速递浆细胞疾病造血干细胞移植与细胞治疗

抗CD38治疗的多发性骨髓瘤患者CD34+细胞动员受损机制研究

Insight into the mechanism of CD34+ cell mobilisation impairment in multiple myeloma patients treated with anti-CD38 therapy.
PubMed 文献 · Br J Haematol · 2023-10-09

研究纳入34例多发性骨髓瘤患者,比较dara-VCd、isa-KRd与VTd方案对CD34+细胞动员的影响,发现含抗CD38方案者CD34+细胞峰值浓度和采集量降低、采集时间延长、植入延迟。对21例患者动员CD34+细胞行RNA-seq,黏附基因过表达,JCAD、NRP2、MDK、ITGA3、CLEC3B为潜在靶基因;体外实验证实isatuximab上调JCAD和CLEC3B。

要点

  • 含抗CD38方案(dara-VCd/isa-KRd)较VTd诱导后CD34+细胞峰值浓度和采集量降低、采集时间延长、植入延迟。
  • 抗CD38方案组采集物和骨髓CD34+亚群比例发生显著变化,但CD38high B淋巴系祖细胞未见减少。
  • RNA-seq显示黏附基因过表达,JCAD、NRP2、MDK、ITGA3、CLEC3B为潜在靶基因;isatuximab体外可上调JCAD和CLEC3B。

核心结论

  • 抗CD38治疗的多发性骨髓瘤患者动员效力下降可能主要由黏附相关相互作用上调导致,而非效应机制杀伤CD34+细胞。

研究设计与样本

  • 研究比较三种诱导方案(dara-VCd、isa-KRd和VTd)对CD34+细胞的影响,共纳入34例患者,采用流式细胞术和转录组学分析。
  • 对21例患者动员的CD34+细胞行RNA-seq,并用定量PCR验证isatuximab的体外直接效应。

主要发现

  • 含抗CD38方案(dara-VCd/isa-KRd)较VTd诱导后CD34+细胞峰值浓度和采集量降低、采集时间延长、植入延迟,共34例患者。
  • 流式细胞术显示抗CD38方案组采集物和骨髓CD34+亚群比例发生重大变化,但两种材料中CD38high B淋巴系祖细胞均未减少。
  • 21例患者动员CD34+细胞的RNA-seq显示,dara-VCd/isa-KRd后黏附基因过表达,JCAD、NRP2、MDK、ITGA3和CLEC3B被确定为潜在靶基因。
  • 定量PCR证实isatuximab在体外直接上调JCAD和CLEC3B。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Induction therapy followed by CD34+ cell mobilisation and autologous transplantation represents standard of care for multiple myeloma (MM). However, the anti-CD38 monoclonal antibodies daratumumab and isatuximab have been associated with mobilisation impairment, yet the mechanism remains unclear. In this study, we investigated the effect of three different regimens (dara-VCd, isa-KRd and VTd) on CD34+ cells using flow cytometry and transcriptomics. Decreased CD34+ cell peak concentration and yields, longer collection and delayed engraftment were reproduced after dara-VCd/isa-KRd versus VTd induction in 34 patients in total. Using flow cytometry, we detected major changes in the proportion of apheresis product and bone marrow CD34+ subsets in patients treated with regimens containing anti-CD38 therapy; however, without any decrease in CD38high B-lymphoid progenitors in both materials. RNA-seq of mobilised CD34+ cells from 21 patients showed that adhesion genes are overexpressed in CD34+ cells after dara-VCd/isa-KRd and JCAD, NRP2, MDK, ITGA3 and CLEC3B were identified as potential target genes. Finally, direct in vitro effect of isatuximab in upregulating JCAD and CLEC3B was confirmed by quantitative PCR. These findings suggest that upregulated adhesion-related interactions, rather than killing of CD34+ cells by effector mechanisms, could be leading causes of decreased mobilisation efficacy in MM patients treated with anti-CD38 therapy.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Venglar O, Kapustova V, Anilkumar Sithara A, et al. Insight into the mechanism of CD34+ cell mobilisation impairment in multiple myeloma patients treated with anti-CD38 therapy. Br J Haematol. 2023. PMID: 37807708. doi:10.1111/bjh.19141

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。